DK3459954T3 - Ny polymorf af triazolo-pyrazin-derivat og fremgangsmåde til fremstilling af samme - Google Patents

Ny polymorf af triazolo-pyrazin-derivat og fremgangsmåde til fremstilling af samme Download PDF

Info

Publication number
DK3459954T3
DK3459954T3 DK18750790.0T DK18750790T DK3459954T3 DK 3459954 T3 DK3459954 T3 DK 3459954T3 DK 18750790 T DK18750790 T DK 18750790T DK 3459954 T3 DK3459954 T3 DK 3459954T3
Authority
DK
Denmark
Prior art keywords
triazolo
preparing
same
pyrazine derivatives
new polymorph
Prior art date
Application number
DK18750790.0T
Other languages
English (en)
Inventor
Seong-Hoon Jeong
Ki-Hyun Kim
Nam-Ah Kim
Original Assignee
Abion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abion Inc filed Critical Abion Inc
Application granted granted Critical
Publication of DK3459954T3 publication Critical patent/DK3459954T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK18750790.0T 2017-02-08 2018-01-24 Ny polymorf af triazolo-pyrazin-derivat og fremgangsmåde til fremstilling af samme DK3459954T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170017440A KR20180092096A (ko) 2017-02-08 2017-02-08 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
PCT/KR2018/001038 WO2018147575A1 (ko) 2017-02-08 2018-01-24 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법

Publications (1)

Publication Number Publication Date
DK3459954T3 true DK3459954T3 (da) 2021-06-21

Family

ID=63107653

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18750790.0T DK3459954T3 (da) 2017-02-08 2018-01-24 Ny polymorf af triazolo-pyrazin-derivat og fremgangsmåde til fremstilling af samme

Country Status (8)

Country Link
US (1) US10538529B2 (da)
EP (2) EP3459954B1 (da)
JP (1) JP6833300B2 (da)
KR (1) KR20180092096A (da)
CN (2) CN114773349A (da)
DK (1) DK3459954T3 (da)
ES (1) ES2875580T3 (da)
WO (1) WO2018147575A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11987582B2 (en) * 2021-01-27 2024-05-21 Abion Inc. Maleate salts of triazolopyrazine derivatives, compositions, methods of use, and processes of manufacturing the same
US20230416255A1 (en) * 2022-06-27 2023-12-28 Abion Inc. Mesylate salts of triazolopyrazine derivatives
US11964979B2 (en) * 2022-06-27 2024-04-23 Abion Inc. Camsylate salts of triazolopyrazine derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DK2361250T3 (da) 2008-12-22 2013-11-04 Merck Patent Gmbh Nye polymorfe former af 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-on-dihydrogenphosphat og fremgangsmåder til fremstilling deraf
US8710058B2 (en) 2009-01-08 2014-04-29 Merck Patent Gmbh Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
EP2719699B1 (en) * 2009-12-31 2015-07-08 Hutchison Medipharma Limited Certain triazolopyrazines, compositions thereof and methods of use therefor
KR101745741B1 (ko) 2012-08-13 2017-06-12 한국화학연구원 신규한 트리아졸로 피라진 유도체 및 그의 용도
CA2923533C (en) 2013-09-30 2019-08-06 Korea Research Institute Of Chemical Technology Triazolopyrazine derivatives and uses thereof

Also Published As

Publication number Publication date
EP3919499B1 (en) 2024-05-01
EP3459954B1 (en) 2021-05-26
EP3459954A1 (en) 2019-03-27
WO2018147575A1 (ko) 2018-08-16
JP6833300B2 (ja) 2021-02-24
CN110049988A (zh) 2019-07-23
ES2875580T3 (es) 2021-11-10
CN114773349A (zh) 2022-07-22
US20190270747A1 (en) 2019-09-05
KR20180092096A (ko) 2018-08-17
CN110049988B (zh) 2022-07-05
EP3919499A1 (en) 2021-12-08
JP2019517496A (ja) 2019-06-24
EP3459954A4 (en) 2019-11-27
US10538529B2 (en) 2020-01-21

Similar Documents

Publication Publication Date Title
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3788044T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
DK3601358T3 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3286181T3 (da) Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3555070T3 (da) Aminsubstituerede, heterocykliske forbindelser som ehmt2-hæmmere og fremgangsmåder til anvendelse deraf
DK3559000T3 (da) Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3368613T3 (da) Matteringsmiddel og fremgangsmåde til fremstilling deraf
DK3447051T3 (da) Fremgangsmåde til fremstilling af tyrosinkinaseinhibitor og derivat deraf
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3606929T3 (da) Beta-nicotinat-ester-nukleotider og fremgangsmåder til fremstilling af samme
DK3178324T3 (da) Mikrobicid og fremgangsmåde til fremstilling af samme
DK3515990T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3429998T3 (da) Fremgangsmåde til fremstilling af quinolin-2-yl-phenylaminderivater og disses salte
DK3572062T3 (da) Vandholdig kapsel og fremgangsmåde til fremstilling af vandholdig kapsel
DK3574135T3 (da) Fremgangsmåde og formulering til fremstilling af ligninfibre
DK3672919T3 (da) Anlæg og fremgangsmåde til fremstilling af cementklinker
DK3265443T3 (da) Pyrrolidincarboxamidderivater og fremgangsmåde til fremstilling og anvendelse af samme
DK3255046T3 (da) Hydroxyethylsulfonat af cyclin-afhængig proteinkinasehæmmer, krystallinsk form deraf og fremgangsmåde til fremstilling deraf
DK3398598T3 (da) Sulfonamidderivat og fremstillingsmetode og anvendelse deraf
DK3495352T3 (da) Krystalformer af en androgenreceptorantagonist, fremgangsmåde til fremstilling og anvendelse deraf
DK3636640T3 (da) Krystal af heterocyclidenacetamidderivat
DK3452424T3 (da) Fremgangsmåde og anlæg til fremstilling af cement